prostate benign epithelial cells results due to increased number of zinc transporter ZIP1 in prostate. Various research's performed on kreb cycle pathway has proved that activity of m-aconitase can be inhibited by high concentration of Zinc [8]. M-aconitase enzyme is mainly responsible for the oxidation of citrate in citrate oxidation or kreb cycle pathway. As we know, cells depends on oxidation of citrate which is a very important step in kreb cycle for the progress of aerobic respiration [9]. High amount of ATP, is produced by production and oxidation of citrate in kreb cycle which is followed by coupled phosphorylation. Various other pathways for biosynthesis of amino acid metabolism and for their degradation, are produced by the kreb cycle and recycling of their intermediates.

**Citation:**

relationship there are needs to use biomarkers other than PSA to easy and early detection of Pca. Biomarkers like TMPRSS2-ERG, PCA3 and exosomes can prove very important for early and easy detection due to their specificity and sensitivity. Researches should be done in this lacked but very important area. While this presentation is highly speculative, it provides a rational basis for various latest perspective to control and elimination of Pca. Hopefully this review will serve to expand interest of the basic and clinical scientific community in addressing these important areas of research.

## Author Contributions

RR and RK Planning and preparation of the manuscript. NKG has guided for preparation of the final manuscript. All authors contributed significantly to the study and have approved the final manuscript.

## Acknowledgments

We sincerely thank Sir Ganga Ram Hospital in providing all the necessary support.

## Conflict of Interest

Authors have conflict of interest.

## Funding

Nil.

### References

1. Claus GR, Black LK. (2011) The economic burden of prostate cancer. Bjui Int 108:806-813.
2. Capper CP, Rae JM, Auchus RJ.(2016) The Metabolism, Analysis, and Targeting of Steroid hormones in breast and prostate cancer. Horm and Cancer; 7:149-164.
3. Lilja H, Ulmert D, Vickers AJ.(2008) Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring. Nat Rev Cancer; 8:268-278.
4. Carlsson SV, Kattan MW.(2016) Personalized risk-stratified screening or abandoning it altogether? Nat Rev Clin Oncol; 13:140-142.
5. Kumar D, Gupta A, Nath K.(2016) NMR-based metabolomics of prostate cancer: A protagonist in clinical diagnostics. Expert Rev Mol Diagn; 16: 651-661.
6. Ferenc Gyorkey, Kyung WM, JA Huff, Phyllis Gyorkey.(1967) Zinc and magnesium in human prostate gland: normal, hyperplastic, and neoplastic. Cancer Res; 27:1348-1353.
7. NK Dhar,